Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 4/20 | 0.54 |
| ▸ | ECE1 | P42892 | 6/20 | 0.50 |
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397778 | 1.00 | PIN1 (0.54) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL852503 | 0.88 | PIN1 (0.67) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL20397877 | 0.87 | PIN1 (0.54) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL20397878 | 0.87 | PIN1 (0.54) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL18262700 | 0.84 | PIN1 (0.54) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL18262698 | 0.84 | PIN1 (0.54) | PIN1ECE1MMEAGTR2NAALAD2 | |
| SCHEMBL20415885 | 0.82 | GRN (0.47) | PIN1ECE1MMEAGTR2GRN | |
| SCHEMBL20397617 | 0.75 | ECE1 (0.46) | PIN1ECE1MMEAGTR2 | |
| SCHEMBL20397620 | 0.75 | ECE1 (0.46) | PIN1ECE1MMEAGTR2 | |
| SCHEMBL21835921 | 0.74 | CYP1A2 (0.43) | PIN1ECE1MMEAGTR2FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, SAAL1, FPR2 | PIN1 3515/4885ECE1 1564/4885MME 1176/4885 |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | PIN1 3357/4885ECE1 1345/4885MME 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.